Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

计划入组 45 人 · 首次发布于 2018 年 8 月 15 日

VDAC1 inhibitors

VDAC1-based decoy peptides

NLS-VPAC1

Vidac Pharma Secures Broad U.S. Patent Protection for Novel Mitochondria-Targeted Cancer Therapy